Gonorrhea is a sexually transmitted infection caused by *Neisseria gonorrhoeae*; global incidence is ≈80 million cases/year (1,2). To treat uncomplicated gonorrhea, the World Health Organization recommends dual therapy with a single-dose extended-spectrum cephalosporin (ESC) (intramuscular ceftriaxone or oral cefixime) and oral azithromycin (3). However, *N. gonorrhoeae* resistance to ESCs and azithromycin was recently reported (4).

A ceftriaxone-resistant strain (FC428) harboring mutations of mosaic *penA* allele 60.001 (*penA*-60.001) and belonging to sequence type (ST) 1903 was detected in Japan in 2015 (5) and has now been reported on all continents (6). A subclone of FC428, which also carried a mosaic *penA*-60.001 gene but belonged to ST13871, was detected in Singapore in 2018 (isolate 18DG342) and in France in 2019 (isolate F91) (7,8). Genomic surveillance of *N. gonorrhoeae* in Vietnam during 2011 and 2015–2016 showed 1%–5% resistance to ceftriaxone that was not associated with *penA*-60.001 (9). In 2019–2020, we detected 15 ST13871 isolates related to the FC428 clone in Vietnam.

### The Study

During June 2019–December 2020, a total of 1,116 *N. gonorrhoeae* isolates were isolated from 6,090 urethral and endocervical swab samples at 3 dermatology and venereology hospitals in Hanoi, Danang, and Ho Chi Minh City, Vietnam. Of these, 427 isolates were sent to a reference laboratory (National Hospital for Tropical Diseases, Hanoi) for antimicrobial susceptibility testing and sequencing. We used disk diffusion (Oxoid, http://www.oxoid.com/uk) to determine susceptibility to penicillin, tetracycline, spectinomycin, ciprofloxacin and an Etest (bioMérieux, https://www.biomerieux.com) for ceftriaxone, cefixime, and azithromycin. We interpreted inhibition zones and MICs according to 2020 Clinical and Laboratory Standards Institute guidelines (10). For whole-genome sequencing, we selected 114 isolates (28/104 from Hanoi, 16/56 from Danang, and 70/267 from Ho Chi Minh City) according to reduced susceptibility to ESC/azithromycin (51/114) or epidemiologic features (travel, men having sex with men, contact with sex worker, multiple partners). This study was approved by the Institutional Ethical Review Board of Hanoi Medical University, Hanoi, Vietnam (518/GCN-HDDDNCYSH-DHYHN, 2021 May 17). All participants gave written informed consent.

After extracting DNA with a DNasey Blood & Tissue kit (QIAGEN, https://www.qiagen.com), we prepared DNA libraries by using Nextera XT library preparation and index kits (Illumina, https://www.illumina.com). We performed sequencing on a MiSeq platform with reagent kit 600 V3 (Illumina). We used fastp version 0.20.0 (GitHub, https://github.com) to filter out low-quality bases with Phred score <30 and to trim off the adapters. We used ARIBA 2.14.6 (GitHub) with a custom database for screening to...
detect antimicrobial resistance genes. We identified multilocus sequence typing (MLST) records from the Neisseria typing scheme PubMLST (https://pubmlst.org). We performed de novo assembly on the processed reads by using Shovill version 1.1.0 with SPades version 3.14 (GitHub) as the assembler. We used MOB-suite version 3.0.0 (GitHub) to reconstruct chromosome and plasmids from the assemblies. We identified N. gonorrhoeae multi-antigen sequence type (NG-MAST) by using NGMaster version 0.5.5, and we used N. gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR) with pyngSTar (GitHub). We used the closest complete genome of N. gonorrhoeae searched by ReferenceSeeker (GitHub) as reference in Snippy 4.6.0 (GitHub) for variant calling. We created the core-genome alignment by using snippy-core with a provided mask of repeated regions and mobile elements. We used Gubbins version 2.3.4 (GitHub) to filter out the recombination in the alignment and fed it into IQTRE2 (GitHub) to reconstruct a maximum-likelihood phylogenetic tree. We used BEAST version 10.4 and TreeAnnotator (https://beast.community) to estimate the time to the most recent common ancestor (tMRCA), and ggtrree version 3.0.2 (GitHub) in R (https://www.r-project.org) for visualization. Sequencing data are available from the European Nucleotide Archive (https://www.ebi.ac.uk/ena; project no. PRJEB45627).

Of 114 N. gonorrhoeae isolates, 15 were typed by MLST as ST13871 (Table). All patients recovered clinically after receiving 1 dose of intramuscular ceftriaxone (1 g) and oral azithromycin (1 g), although microbiological clearance of N. gonorrhoeae was unknown. However, because neither test-of-cure nor pharyngeal testing was performed, persistent asymptomatic infection may have been missed.

Among the 15 ST13871 isolates, NG-MAST based on 2 antigen genes identified 7 as ST7237 and 1 as ST1086; 7 were of unidentified sequence type (porB new, tbpB 21). In the NG-STAR system, based on 7 resistance genes, we found that 6 isolates were ST233, 1 was ST345, 1 was ST1133; sequence types were unknown for 7 (Appendix, https://wwwnc.cdc.gov/EID/article/28/02/21-1788-App1.pdf). For 1 isolate from Vietnam, the MLST, NG-MAST, and NG-STAR typing was identical to that of the 2 strains reported from Singapore and France/Cambodia (Appendix).

All ST13871 isolates were resistant to ciprofloxacin, nonsusceptible to penicillin and tetracycline, but susceptible to spectinomycin. For 14 isolates, susceptibility to ESCs was reduced (MIC ranges: cefixime 0.5–1.5 mg/L, ceftriaxone 0.38–0.75 mg/L) and 3 were nonsusceptible to azithromycin (MIC 1.5 mg/L), thus presenting an extensively drug-resistant (XDR) pattern (11) (Appendix).

| Variable                                      | No. (%) |
|-----------------------------------------------|---------|
| Patient sex                                   |         |
| M                                             | 13 (87) |
| F                                             | 2 (13)  |
| Place of consultation, year                   |         |
| Ho Chi Minh City, 2019                        | 3 (20)  |
| Ho Chi Minh City, 2020                        | 9 (60)  |
| Danang, 2020                                  | 3 (20)  |
| Hanoi                                        | 0       |
| Clinical history                              |         |
| Previous STIs                                 | 0       |
| Co-infection with other STIs                  | 0       |
| Syphilis                                      | 0       |
| Chlamydia trachomatis                         | 0       |
| Sexual history                                |         |
| Sex partners during past 3 mo                 |         |
| 1                                             | 10 (67) |
| 2                                             | 5 (33)  |
| Sexual contact with commercial sex worker     | 5 (33)  |
| Unprotected sex during most recent intercourse | 12 (80) |
| Men who have sex with men                     |         |
| Current treatment with antibiotic             |         |
| Ceftriaxone, 1g intramuscularly               |         |
| Azithromycin, 1g orally                       |         |

*Patient age range (median) 19–56 (31) y, ST, sequence type; STIs, sexually transmitted infections.

Most ST13871 isolates harbored resistance genes, including penA: L421P, the plasmid-mediated bla-TEM 135, the mtrR promoter −35Adel mutation causing overexpression of the MtrCDE efflux pump, rpsJ: V57M associated with tetracycline resistance, or changes in penB (G120K, A121D) associated with decreased influx of porin channel PorB1b. The mosaic penA-60.001, associated with resistance to ESCs (5), was found in 14 of 15 isolates, all nonsusceptible to ≥1 ESC (Appendix). One ST13871 isolate carrying penA-43.002 gene was susceptible to ESCs.

In all 15 isolates, we found mutations in gyrA and parC genes, conferring resistance to ciprofloxacin, including gyrA: S91F/G95A and parC: S87R, and 2 mutations (parC: V596I, L479F) not previously reported. We found no plasmidborne tetM causing resistance to tetracycline and no other gene except for mtrR promoter −35Adel conferring resistance to azithromycin.

According to time-scaled Bayesian phylogeny of 17 ST13871 sequences from Vietnam (n = 15), France (n = 1), and Singapore (n = 1) (Figure), samples clustered into 3 distinct clades. Clade 1a contained the 2 previously reported ST13871 isolates from Singapore and France/Cambodia, as well as 3 isolates from this study, including the one sharing the same typing as the international isolates. Median tMRCA of this clade was calculated as March 2017 (95% highest
posterior density [HPD] April 2014–February 2018), of clade 1b as October 2018 (95% HPD August 2016–September 2019), and of clade 2 as September 2017 (95% HPD April 2013–May 2019). Estimated median tMRCA for the 17 ST13871 isolates was September 2014. One clade 1b isolate came from a patient who reported having had sexual contact in Laos 1 week before diagnosis. Two of the XDR isolates belonged to clade 2 but were not closely related.

Conclusions
We detected the globally disseminated FC428-related resistant \textit{N. gonorrhoeae} clone in Vietnam in 2019–2020. Among 114 \textit{N. gonorrhoeae} isolates collected, 15 were ST13871 and 14 were related to the FC428 clone by harboring the mosaic \textit{penA}–60.001 gene conferring resistance to ESCs. The ceftriaxone MICs for these 14 isolates were similar to those for globally reported FC428 isolates, but cefixime MICs were lower (6,12). We found 3 XDR ST13871 isolates, nonsusceptible to azithromycin and ESCs but susceptible to spectinomycin. Resistance determinants to other antimicrobial drugs in all isolates from Vietnam were similar to those of the FC428 clone (5,7,8,13,14).

Our phylogenetic analysis showed that all 17 ST13871 isolates arose from the rooted FC428 strain and were distributed into 3 clades with a common ancestor estimated in 2014, consistent with estimates of other FC428-like isolates (13). These results suggest that ST13871 has been circulating in Southeast Asia for several years.

Emergence of multidrug-resistant FC428 subclone (ST13871) in Vietnam possibly threatens effectiveness of the current presumptive treatment. Therefore, regular monitoring of antimicrobial drug susceptibility of \textit{N. gonorrhoeae} is necessary. Controlling the spread of resistant \textit{N. gonorrhoeae} may be enhanced by follow-up visits, postrecovery culturing, and partner counseling.

Acknowledgments
We thank the laboratory technicians at the Department of Microbiology, National Hospital of Dermatology and Venereology; Ho Chi Minh Hospital of Dermatology and Venereology; and Danang Hospital of Dermatology and Venereology for collecting swab samples and isolating \textit{N. gonorrhoeae}. We acknowledge the laboratory staff at Oxford University Clinical Research Unit, Hanoi, for their support with sample processing and whole-genome sequencing.
This work was conducted with funding from Wellcome (106680), the Fleming Fund pilot grant Vietnam (Department of Health and Social Care, UK), and the Vietnam Fleming Fund Country Grant (Department of Health and Social Care, UK), managed by Mott MacDonald and awarded to FHI360 (FHI360 FF15/184) with a subcontract to OUCRU/University of Oxford (PO20001070), although the views expressed in this publication do not necessarily reflect those of FHI360 or Mott MacDonald. The funders had no role in study design, data collection and analysis, or the decision to publish.

About the Author
Dr. Trinh is a medical doctor at National Hospital of Dermatology and Venereology, Hanoi, Vietnam, and a member of the project of technical assistance and capacity building for identification and antimicrobial susceptibility testing for N. gonorrhoeae in the Dermatology and Venereology system in Vietnam. Her research interests are surveillance and molecular mechanisms of antimicrobial resistance of N. gonorrhoeae in Vietnam.

References
1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One. 2015;10:e0143304. https://doi.org/10.1371/journal.pone.0143304
2. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97:548–562P. https://doi.org/10.2471/BLT.18.228486
3. World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. 2016 [cited 2021 Apr 3]. https://www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en/
4. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587–613. https://doi.org/10.1128/CMR.00010-14
5. Nakayama S, Shimuta K, Furubayashi K, Kawahata T, Unemo M, Ohnishi M. New ceftriaxone-and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob Agents Chemother. 2016;60:4339–41. https://doi.org/10.1128/AAC.00504-16
6. Chen S-C, Yuan L-F, Zhu X-Y, van der Veen S, Yin Y-P. Sustained transmission of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in China. J Antimicrob Chemother. 2020;75:2499–502. https://doi.org/10.1093/jac/dkaa196
7. Poncin T, Merimeche M, Braille A, Mainardis M, Bebear C, Jacquier H, et al. Two cases of multidrug-resistant Neisseria gonorrhoeae related to travel in south-eastern Asia, France, June 2019. Euro Surveill. 2019;24:1900528. https://doi.org/10.2807/1560-7917.ES.2019.24.36.1900528
8. Ko K, Chio M, Goh S, Tan A, Koh T, Rahman N. First case of ceftriaxone-resistant multidrug-resistant Neisseria gonorrhoeae in Singapore. Antimicrob Agents Chemother. 2019;63:e02624-18.
9. Lan PT, Golparian D, Ringlander J, Van Hung L, Van Thuong N, Unemo M. Genomic analysis and antimicrobial resistance of Neisseria gonorrhoeae isolates from Vietnam in 2011 and 2015–16. J Antimicrob Chemother. 2020;75:1432–8. https://doi.org/10.1093/jac/dkaa040
10. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing, 30th edition (M100). Wayne (PA): The Institute; 2020.
11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x
12. Yan J, Chen Y, Yang F, Ling X, Jiang S, Zhao F, et al. High percentage of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone among isolates from a single hospital in Hangzhou, China. J Antimicrob Chemother. 2021;76:936–9. https://doi.org/10.1093/jac/dkaa526
13. Eyre DW, Town K, Street T, Barker L, Sanderson N, Cole MJ, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro Surveill. 2019;24:1900147. https://doi.org/10.2807/1560-7917.ES.2019.24.10.1900147
14. Lahra MM, Martin I, Demczuk W, Jennison AV, Lee K-I, Nakayama S-I, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis. 2018;24:735–40. https://doi.org/10.3201/eid2404.171873

Address for correspondence: Tam T. Nguyen, Oxford University Clinical Research Unit, National Hospital for Tropical Diseases, No.78 Giai Phong St, Dong Da District, Hanoi, Vietnam; email: tamnt@oucru.org
Neisseria gonorrhoeae FC428 Subclone, Vietnam, 2019–2020

Appendix

Phylogenetic tree of Neisseria gonorrhoeae ST13871 samples including 15 isolates from Vietnam during 2019–2020, 1 from Singapore (18DG342), and 1 from France (F91), the FC428 strain was used as an outgroup. Sequence types from the MLST, NG-MAST, NGSTAR database; phenotypes and AMR determinants are displayed. Sequence types that have not yet been assigned with a number are indicated as a dash. The phenotypes include Resistance (R), Susceptible (S), Intermediate (I) and Non-susceptible (NS). AMR determinants are antimicrobial resistance gene and their amino acid changes; asterisk symbol (*) refers to a novel mutation. NA (not available) represents phenotypes or resistance genes that were not reported. CIP: ciprofloxacin, P: penicillin, SPT: spectinomycin, TE: tetracycline, AZM: azithromycin, CFM: cefixime, CRO: ceftriaxone.